# A Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of RBD4059 in Participants With Stable Coronary Artery Disease

> **NCT06717074** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Ribocure Pharmaceuticals AB** · enrollment: 30 (estimated)

## Conditions studied

- Stable Coronary Artery Disease CAD

## Interventions

- **DRUG:** RBD4059
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06717074
- **Lead sponsor:** Ribocure Pharmaceuticals AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-08-28
- **Primary completion:** 2026-04-28
- **Final completion:** 2026-04-28
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06717074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06717074, "A Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of RBD4059 in Participants With Stable Coronary Artery Disease". Retrieved via AI Analytics 2026-08-16 from https://api.ai-analytics.org/clinical/NCT06717074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*